ClinicalTrials.gg
CompletedNCT01806298Updated Dec 2, 2017Results posted

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

A Phase 4 interventional study of Saizen® solution for injection (referred as Saizen®) in Adult Growth Hormone Deficiency, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 19 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-12-02.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
28th of 60
78 · median 66
Started
2013
with 1 other
Phase 4
19 of 60
none open now
Registered
45th of 60
by date
Lead sponsor
4 of 60
Merck KGaA, Darmstadt, Germany

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 28th largest by enrollment, is one of 2 that started in 2013, is one of 19 in phase 4, and was the 45th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

This is an open-label, single-arm, multicenter, Phase 4 study to explore the immunogenicity of the liquid formulation of Saizen® in subjects with Adult Growth Hormone Deficiency (AGHD), who are growth hormone (GH) treatment-naïve or who had prior GH treatment for GHD which was stopped at least 1 month prior to Screening and have no contraindication to the use of GH.

03

Conditions studied

  • Adult Growth Hormone Deficiency

Browse trials for

Keywords

  • Adult Growth hormone deficiency
  • Saizen®
  • Recombinant human growth hormone (r-hGH)
  • Somatropin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, 18-65 years of age, inclusive, at the time of signature of
  • Documented AGHD i.e. childhood onset (CO) or adult onset (AO), either by a stimulation test as described in the GH Research Society's 2007 guidelines for the diagnosis and treatment of AGHD, or in the Saizen® label, whichever is more stringent, or by confirming the presence of at least 3 pituitary hormone deficiencies and an IGF-1 level below the reference range of the laboratory where testing is performed. Stimulation test as described in the 2007 GH Research Society guidelines and applicable to all subjects who underwent or will undergo a stimulation test:

    • Insulin Tolerance Test (ITT) or glucagon stimulation test: Peak GH less than 3 nanogram per milliliter (ng/mL);
    • GH-releasing hormone (GHRH) plus arginine test, peak GH depends on (BMI):

      • BMI less than 25 kilogram per square meter (kg/m\^2) indicates a peak GH less than 11 ng/mL microgram per liter [mcg/L]).
      • BMI 25-30 kg/m\^2 indicates a peak GH less than 8 ng/mL (mcgg/L).
      • BMI greater than 30 kg/m\^2 indicates a peak GH less than 4 ng/mL (mcg/L).

Clonidine, l-dopa, and arginine alone are not acceptable as stimulation tests for determining eligibility in this trial. Stimulation tests remain under the Investigator's or the subject's physician's responsibility, including the selection of the GH assay. Saizen® label: in Europe, only one single test is required; in Australia, 2 stimulation tests showing a peak GH less than 2.5 ng/mL are required. The inclusion criteria were chosen based on the approved label for Saizen® in the countries where the trial is being implemented, as well as in respect of the most current international guidelines for AGHD. There is no limit in time prior to the Screening visit for the stimulation test(s), as long as documentation is available and the stimulation tests comply with the GH Research Society 2007 guidelines, and as such, there is no need to repeat the test for subjects having stopped their GH therapy prior to the Screening visit. No stimulation test is required for subjects with 3 or more pituitary hormone deficiencies

  • GH treatment-naïve or prior GH treatment for AGHD stopped at least 1 month prior to Screening visit. Whereas any prior use of GH is permitted, providing an adequate is respected to secure the interpretation of the biomarkers, the reason for stopping the GH therapy should neither be safety- nor efficacy-related, and documentation should be present in the source information
  • Negative BAbs from the Screening visit sample
  • Body mass index (BMI, Weight in kilograms / Height in square meters) measured at Screening visit as less than or equal to 35 kilogram per square meter (kg/m\^2)
  • Negative serum pregnancy test at the Screening for women of and subject is not lactating
  • Understanding and willingness of the subject to comply with the procedures of the study
  • Informed Consent form signed prior to the performance of any trial-related activities

Exclusion criteria

Exclusion Criteria:

  • to the active substance or to any of the Saizen®
  • Evidence of growing intracranial tumor including pituitary tumor, or affecting the optic chiasm, or requiring treatment (surgery or radiation) within the 6 months prior to and the 12 months after the Screening visit
  • Presence of active , neoplasia or any evidence of progression or recurrence of an underlying tumor. In case of a history of neoplasia or any pre-existing malignancy, the tumor must be inactive and anti-tumor therapy completed prior to starting trial on active Saizen® therapy.
  • Proliferative or pre-proliferative diabetic retinopathy
  • Evidence of chronic underlying disease within 6 months prior to the Screening visit or concomitant medication that would interfere with subject compliance, the evaluation of trial results, or compromise the safety of the subject
  • Severe hepatic or renal failure that could compromise the interpretation of IGF-1, that is: [ALT] or aspartate transaminase [AST] greater than 3 * ; (GFR) less than 30 milliliter per minute (mL/min) Note: GFR will be calculated by the laboratory according to the Modification of Diet in Renal Disease (MDRD) equation
  • History of anti-GH antibodies
  • History or presence of an disease, such as Hashimoto's disease or Systemic Lupus Erythematosus (SLE), regardless of etiology, or GH1 gene defect
  • Absence of effective in place at the Screening visit in women of . Acceptable forms of effective contraception include: established use of oral (greater than 2 months), injected, or implanted hormonal methods of contraception, intrauterine devices (IUD), or barrier methods of contraception, specifically, condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
  • Diabetes mellitus (per American Diabetes Association 2010 guidelines): either i) standard diabetes symptoms and a random glucose greater than or equal to 200 milligram per deciliter (mg/dL) (11.1 millimolar per liter [mmol/L]); ii) a fasting plasma glucose greater than 126 mg/dL (6.99 mmol/L); iii) a 2-hour plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT); or iv) an glycosylated () greater than or equal to 6.5 percent
  • Concomitant or prior participation in an interventional trial within 30 days prior to the Screening visit
  • Known alcohol or drug addiction/dependency
  • Has a legal incapacity or limited legal capacity
  • Has received anabolic steroids (except for gonadal replacement therapy) or systemic corticosteroids (except for replacement doses) within 3 months prior to the Screening visit
  • Has received substitutive therapy with glucocorticosteroids, thyroid replacement, vasopressin, or sex hormones for less than 3 months or substitutive therapy has not been stable (that is, dose was not generally constant or medical condition was not controlled) for 3 months prior to Screening
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Saizen®

    Drug: Saizen® solution for injection (referred as Saizen®)

Interventions

  • Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.

    Also known as: Somatropin, Recombinant human growth hormone (r-hGH)

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Developing Binding Antibodies (BAbs) to Saizen®

    Percentage of subjects developing BAbs = (Number of BAb positive subjects / Total number of subjects) x 100.

    Time frame: Baseline up to Week 39

Secondary outcomes

  1. Percentage of Subjects With Binding Antibodies (BAbs) Who Became Positive for Neutralizing Antibodies (NAbs)

    Percentage of subjects with BAbs who become positive for NAbs = (Number of NAb positive subjects / Number of BAbs positive subjects) x 100

    Time frame: Baseline up to Week 39

  2. Insulin-like Growth Factor-I (IGF-I) Levels

    Growth Hormone (GH) biomarker levels were summarized by GH treatment status at study entry (that is subjects were classified as GH treatment-naïve subjects or subjects with prior GH treatment for adult growth hormone deficiency \[AGHD\]).

    Time frame: Baseline, Week 2, 8, 16, 29, 39 and 41

  3. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels

    Growth Hormone (GH) biomarker levels were summarized by GH treatment status at study entry (that is subjects were classified as GH treatment-naïve subjects or subjects with prior GH treatment for adult growth hormone deficiency \[AGHD\])

    Time frame: Baseline, Week 2, 8, 16, 29, 39 and 41

  4. Insulin-like Growth Factor-I Standard Deviation Score (IGF-I SDS)

    Insulin-like Growth Factor-1 SDS was calculated based on the actual value of IGF-1 minus reference value of IGF-1 divided by reference standard deviation of IGF-1. SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a subject's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated that the IGF-I value was lower compared to the reference population.

    Time frame: Baseline, Week 2, 8, 16, 29, 39 and 41

  5. Treatment Adherence Rate as Documented Using EasypodTM Connect

    Treatment adherence rate was measured by: (total dose received divided by total dose prescribed) multiplied by 100. Saizen solution for injection was administered using the easypod device and treatment adherence information was obtained from the device using the easypod connect software.

    Time frame: Week 2, 8, 16, 29 and 39

Other outcomes

  1. Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, TEAEs Leading to Discontinuation

    An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are those events with onset dates occurring during the on-treatment period or if the worsening of an event is during the on-treatment period. TEAEs include both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Week 41

07

Results

Posted Apr 4, 2017

Participant flow

Participant flow — Overall Study
MilestoneSaizen®
Started78
Completed68
Not completed10
Withdrew: Adverse event3
Withdrew: Protocol non-compliance1
Withdrew: Withdrawal by subject1
Withdrew: Other5

Outcome measures

PrimaryPercentage of Subjects Developing Binding Antibodies (BAbs) to Saizen®

Percentage of subjects developing BAbs = (Number of BAb positive subjects / Total number of subjects) x 100.

Time frame:
Baseline up to Week 39
Reported as:
Number · percentage of subjects
Percentage of Subjects Developing Binding Antibodies (BAbs) to Saizen®
percentage of subjectsSaizen®
Percentage of Subjects Developing Binding Antibodies (BAbs) to Saizen®0 (0.00 to 4.68)
SecondaryPercentage of Subjects With Binding Antibodies (BAbs) Who Became Positive for Neutralizing Antibodies (NAbs)

Percentage of subjects with BAbs who become positive for NAbs = (Number of NAb positive subjects / Number of BAbs positive subjects) x 100

Time frame:
Baseline up to Week 39

No measurements were reported for this outcome.

SecondaryInsulin-like Growth Factor-I (IGF-I) Levels

Growth Hormone (GH) biomarker levels were summarized by GH treatment status at study entry (that is subjects were classified as GH treatment-naïve subjects or subjects with prior GH treatment for adult growth hormone deficiency \[AGHD\]).

Time frame:
Baseline, Week 2, 8, 16, 29, 39 and 41
Reported as:
Mean · nanomoles per liter (nmol/L)
Insulin-like Growth Factor-I (IGF-I) Levels
nanomoles per liter (nmol/L)Saizen®
GH Treatment-naive: Baseline14.54 ± 7.219
Previously took GH treatment : Baseline10.91 ± 4.744
GH Treatment-naive: Week 221.15 ± 9.008
Previously took GH treatment: Week 219.41 ± 5.804
GH Treatment-naive: Week 823.41 ± 9.070
Previously took GH treatment: Week 820.91 ± 5.437
GH Treatment-naive: Week 1622.34 ± 6.844
Previously took GH treatment: Week 1620.15 ± 7.381
GH Treatment-naive: Week 2925.07 ± 8.026
Previously took GH treatment: Week 2920.90 ± 6.810
GH Treatment-naive: Week 3923.82 ± 7.961
Previously took GH treatment: Week 3920.56 ± 8.486
GH Treatment-naive: Week 4115.28 ± 6.943
Previously took GH treatment: Week 4112.12 ± 4.910
SecondaryInsulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels

Growth Hormone (GH) biomarker levels were summarized by GH treatment status at study entry (that is subjects were classified as GH treatment-naïve subjects or subjects with prior GH treatment for adult growth hormone deficiency \[AGHD\])

Time frame:
Baseline, Week 2, 8, 16, 29, 39 and 41
Reported as:
Mean · milligram/liter (mg/L)
Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels
milligram/liter (mg/L)Saizen®
GH Treatment-naive: Baseline2.62 ± 0.843
Previously took GH treatment : Baseline2.20 ± 0.680
GH Treatment-naive: Week 23.03 ± 0.872
Previously took GH treatment: Week 22.85 ± 0.981
GH Treatment-naive: Week 83.11 ± 0.831
Previously took GH treatment: Week 82.77 ± 0.795
GH Treatment-naive: Week 163.15 ± 0.746
Previously took GH treatment: Week 162.93 ± 0.746
GH Treatment-naive: Week 293.36 ± 0.737
Previously took GH treatment: Week 293.22 ± 0.903
GH Treatment-naive: Week 393.45 ± 0.938
Previously took GH treatment: Week 393.03 ± 0.853
GH Treatment-naive: Week 412.91 ± 0.758
Previously took GH treatment: Week 412.63 ± 0.786
SecondaryInsulin-like Growth Factor-I Standard Deviation Score (IGF-I SDS)

Insulin-like Growth Factor-1 SDS was calculated based on the actual value of IGF-1 minus reference value of IGF-1 divided by reference standard deviation of IGF-1. SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) a subject's value was relative to the mean of the reference population. The scores were centered around zero. Negative score indicated that the IGF-I value was lower compared to the reference population.

Time frame:
Baseline, Week 2, 8, 16, 29, 39 and 41
Reported as:
Mean · Standard deviation score
Insulin-like Growth Factor-I Standard Deviation Score (IGF-I SDS)
Standard deviation scoreSaizen®
GH Treatment-naive: Baseline-3.27 ± 0.816
Previously took GH treatment : Baseline-3.67 ± 1.223
GH Treatment-naive: Week 2-3.10 ± 0.775
Previously took GH treatment: Week 2-3.46 ± 1.140
GH Treatment-naive: Week 8-3.05 ± 0.769
Previously took GH treatment: Week 8-3.16 ± 0.697
GH Treatment-naive: Week 16-3.09 ± 0.799
Previously took GH treatment: Week 16-3.17 ± 0.652
GH Treatment-naive: Week 29-3.01 ± 0.773
Previously took GH treatment: Week 29-3.17 ± 0.713
GH Treatment-naive: Week 39-3.02 ± 0.780
Previously took GH treatment: Week 39-3.44 ± 1.290
GH Treatment-naive: Week 41-3.23 ± 0.830
Previously took GH treatment: Week 41-3.31 ± 0.690
SecondaryTreatment Adherence Rate as Documented Using EasypodTM Connect

Treatment adherence rate was measured by: (total dose received divided by total dose prescribed) multiplied by 100. Saizen solution for injection was administered using the easypod device and treatment adherence information was obtained from the device using the easypod connect software.

Time frame:
Week 2, 8, 16, 29 and 39
Reported as:
Mean · percentage of treatment adherence
Treatment Adherence Rate as Documented Using EasypodTM Connect
percentage of treatment adherenceSaizen®
Treatment Adherence Rate as Documented Using EasypodTM Connect89.3 ± 13.35
Other pre-specifiedNumber of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, TEAEs Leading to Discontinuation

An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are those events with onset dates occurring during the on-treatment period or if the worsening of an event is during the on-treatment period. TEAEs include both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Week 41
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, TEAEs Leading to Discontinuation
ParticipantsSaizen®
TEAEs72
Serious TEAEs4
TEAEs Leading to Death0
TEAEs Leading to Discontinuation4

Adverse events

Collected over Baseline up to Week 41. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saizen®—4/78 (5.1%)65/78 (83.3%)
Most frequent serious events
Most frequent serious events
EventSaizen®
InfectionInfections and infestations1/78
PneumoniaInfections and infestations1/78
Iron deficiency anaemiaBlood and lymphatic system disorders1/78
OesophagitisGastrointestinal disorders1/78
Non-cardiac chest painGeneral disorders1/78
Most frequent other events
Showing 10 of 51
Most frequent other events
EventSaizen®
HeadacheNervous system disorders27/78
NasopharyngitisInfections and infestations21/78
ArthralgiaMusculoskeletal and connective tissue disorders13/78
Back painMusculoskeletal and connective tissue disorders10/78
FatigueGeneral disorders7/78
Injection site bruisingGeneral disorders7/78
DiarrhoeaGastrointestinal disorders6/78
InfluenzaInfections and infestations6/78
Upper respiratory tract infectionInfections and infestations6/78
Lower respiratory tract infectionInfections and infestations5/78

Baseline characteristics

The safety analysis set included all treated subjects who had received at least 1 administration of Saizen®.

Age, Continuous
Age, Continuous(years)Saizen®
Mean44.5 ± 12.61
Sex: Female, Male
Sex: Female, Male(Participants)Saizen®
Female30
Male48
08

Study locations

19 sites
  • Research site
    Adelaide, South Australia 5041, Australia
  • Research site
    Perth, Western Australia 6009, Australia
  • Research site
    Clayton, 3168, Australia
  • Research site
    Darlinghurst, 2010, Australia
  • Research site
    Fitzroy, 3065, Australia
  • Research site
    Berlin, 13344, Germany
  • Research site
    Oldenburg, 26122, Germany
  • Research site
    Würzburg, 97080, Germany
  • Research site
    Goteborg, 41345, Sweden
  • Research site
    Stockholm, 17176, Sweden
  • Research site
    Birmingham, United Kingdom
  • Research site
    Cleveland, TS4 3BW, United Kingdom
  • Research site
    Guildford, GU2 7XX, United Kingdom
  • Research site
    Liverpool, L69 3PX, United Kingdom
  • Research site
    Manchester, M20 4BX, United Kingdom
  • Research site
    Manchester, M6 8HD, United Kingdom
  • Research site
    Norfolk, PE30 4ET, United Kingdom
  • Research site
    Oxford, OX3 7LJ, United Kingdom
  • Research site
    Truro, TR1 3LJ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2013
First posted
Mar 7, 2013
Start
Jun 2013
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results first posted
Apr 4, 2017
Last update
Dec 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01806298
Responsible party
Sponsor
First posted
Mar 7, 2013
Start date
Jun 2013
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Apr 4, 2017
Last update
Dec 2, 2017

Study contacts

Medical Director
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion